Viewing data from:

PHENYTOIN SODIUM

ANDA

PHENYTOIN SODIUM | A040573 | ACELLA PHARMACEUTICALS LLC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Phenytoin Sodium (2023)

Total Spending

$4K

Total Claims

Beneficiaries

Avg Cost/Unit

$0.76

Spending Trend

$2K(2019)→$2K(2020)→$4K(2021)→$5K(2022)→$4K(2023)

YoY Change:+40.2%

5yr CAGR:+9.8%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain6 active DMFs

6 active API suppliers hold Drug Master Files for this ingredient.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPAPHENYTOIN SODIUM

DMF 45381982

ERREDUE SPA INNOVATIVE CHEMICAL AND LIFEPHENYTOIN SODIUM

DMF 163012002

HARMAN FINOCHEM LTDPHENYTOIN SODIUM USP

DMF 178622004

KUNSHAN ORIENTAL PHARMACEUTICAL CO LTDPHENYTOIN SODIUM

DMF 204332007

ORCHID PHARMA LTDPHENYTOIN SODIUM

DMF 204532007

UNICHEM LABORATORIES LTDPHENYTOIN SODIUM USP

DMF 326762018

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 50MG/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Sep 13, 2006

No patent or exclusivity listings for this strength.